Comparison 4.

Cyclosporin versus mycophenolate mofetil with pulse dexamethasone

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment response at 52 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Complete remission (primary outcome 1,2)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Partial remission (primary outcome 3)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 Complete or partial remission (primary outcome 1,2,3)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Sustainable remission between 52 and 78 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 Complete remission (secondary outcome 1,2)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Partial remission (secondary outcome 3)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 No sustainable remission (secondary outcome 4,5)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 CKD or death	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 Death by 52 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 50% decline in GFR by 78 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 ESKD by 78 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Adverse events (weeks 0 to 26)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Serious infection requiring hospitalisation	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Total Infections	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Total hospitalisations	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.4 Gastrointestinal adverse effects	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.5 Neuropsychiatric conditions	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.6 Hypertension	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]